Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyperpolarized 13C-urea is a diagnostic imaging probe used in carbon-13 magnetic resonance imaging (MRI) to assess tissue perfusion and vascularity. It is generated through dissolution dynamic nuclear polarization (DNP), a process that increases the nuclear spin polarization of 13C nuclei, providing a temporary but massive increase in MRI signal sensitivity. Unlike 13C-pyruvate, which is metabolized into lactate or bicarbonate to provide information on metabolic flux, 13C-urea is metabolically inert in human tissues. This metabolic stability makes it an ideal co-polarized tracer for measuring blood flow and providing a reference for perfusion-independent metabolic quantification. It is primarily being investigated in clinical research settings, including studies of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and various cancers, to better characterize the hemodynamic environment of diseased tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyperpolarized 13C-urea.